Literature DB >> 19097981

Persistent inactivation of macrophage cyclooxygenase-2 in mycobacterial pulmonary inflammation.

Tsutomu Shinohara1, Traci Pantuso, Shizuka Shinohara, Mari Kogiso, Quentin N Myrvik, Ruth Ann Henriksen, Yoshimi Shibata.   

Abstract

The induction of cyclooxygenase-2 (COX-2) in tissue macrophages (MØ) increases prostaglandin E(2) (PGE(2)) release, potentially down-regulating granulomatous inflammation. In response to Mycobacteria, local MØ express COX-2, which is either nuclear envelope (NE)-associated or NE-dissociated. Persistent mycobacterial pulmonary inflammation is characterized by alveolar MØ expressing NE-dissociated (inactive) COX-2 without release of PGE(2). In this study, we examined COX-2 in alveolar MØ after intranasal exposure to heat-killed Mycobacterium bovis BCG (HK-BCG). After administration, whole lungs of C57Bl/6 mice were lavaged with saline; COX-2 expression and PGE(2) release by alveolar MØ and tumor necrosis factor (TNF)-alpha and nitric oxide levels in the lung lavage were monitored. Normal alveolar MØ had undetectable levels of COX-2 on Western blots. However, 1 day after intranasal administration, almost all alveolar MØ had phagocytosed HK-BCG and expressed NE-dissociated COX-2 without any increase in the release of PGE(2). At 28 days after intranasal administration, 68% of alveolar MØ still contained both BCG and the NE-dissociated form of COX-2. NE-associated (active) COX-2 was not observed in alveolar MØ. In contrast, 7 days after intraperitoneal injection of HK-BCG, peritoneal MØ containing HK-BCG were no longer detected. At 28 days after intranasal administration, TNF-alpha and nitrite levels in the lung lavage fluid were significantly higher than those in controls. Our results indicate that mycobacterial pulmonary inflammation is associated with suppressed PGE(2) production by alveolar MØ, with expression of COX-2 dissociated from the NE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19097981      PMCID: PMC2715904          DOI: 10.1165/rcmb.2008-0230OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  50 in total

1.  The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum.

Authors:  J C Otto; W L Smith
Journal:  J Biol Chem       Date:  1994-08-05       Impact factor: 5.157

2.  Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection.

Authors:  T Sakuma; T Suenaga; I Yoshida; M Azuma
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

3.  Eicosanoid production by peritoneal and splenic macrophages in mice depleted of bone marrow by 89Sr.

Authors:  Y Shibata; A P Bautista; S N Pennington; J L Humes; A Volkman
Journal:  Am J Pathol       Date:  1987-04       Impact factor: 4.307

4.  Prostacyclin synthesis in ovine pulmonary artery is developmentally regulated by changes in cyclooxygenase-1 gene expression.

Authors:  T S Brannon; A J North; L B Wells; P W Shaul
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

5.  Modulation of tumoricidal activity, induced in bone-marrow-derived mononuclear phagocytes by interferon gamma or Corynebacterium parvum, by interferon beta, tumor necrosis factor, prostaglandin E2, and transforming growth factor beta.

Authors:  R Keller; R Keist; P H van der Meide
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

6.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

7.  Immunological significance of Mycobacterium leprae cell walls.

Authors:  J Melancon-Kaplan; S W Hunter; M McNeil; C Stewart; R L Modlin; T H Rea; J Convit; P Salgame; V Mehra; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease.

Authors:  E G Engleman; G Sonnenfeld; M Dauphinee; J S Greenspan; N Talal; H O McDevitt; T C Merigan
Journal:  Arthritis Rheum       Date:  1981-11

9.  Expression and role of cyclooxygenase isoforms in alveolar and peritoneal macrophages.

Authors:  J Wilborn; D L DeWitt; M Peters-Golden
Journal:  Am J Physiol       Date:  1995-02

10.  Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.

Authors:  T C van der Pouw Kraan; L C Boeije; R J Smeenk; J Wijdenes; L A Aarden
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  4 in total

1.  Chitin particles induce size-dependent but carbohydrate-independent innate eosinophilia.

Authors:  Mari Kogiso; Akihito Nishiyama; Tsutomu Shinohara; Masataka Nakamura; Emiko Mizoguchi; Yoshinori Misawa; Elisabeth Guinet; Mahyar Nouri-Shirazi; C Kathleen Dorey; Ruth Ann Henriksen; Yoshimi Shibata
Journal:  J Leukoc Biol       Date:  2011-03-29       Impact factor: 4.962

2.  Cholera toxin induces a shift from inactive to active cyclooxygenase 2 in alveolar macrophages activated by Mycobacterium bovis BCG.

Authors:  Mari Kogiso; Tsutomu Shinohara; C Kathleen Dorey; Yoshimi Shibata
Journal:  Infect Immun       Date:  2012-11-12       Impact factor: 3.441

3.  Role of PPARγ in COX-2 activation in mycobacterial pulmonary inflammation.

Authors:  Mari Kogiso; Tsutomu Shinohara; C Kathleen Dorey; Yoshimi Shibata
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

4.  Assessment of Physicochemical and In Vivo Biological Properties of Polymeric Nanocapsules Based on Chitosan and Poly(N-vinyl pyrrolidone-alt-itaconic anhydride).

Authors:  Kheira Zanoune Dellali; Mohammed Dellali; Delia Mihaela Raţă; Anca Niculina Cadinoiu; Leonard Ionut Atanase; Marcel Popa; Mihaela-Claudia Spataru; Carmen Solcan
Journal:  Polymers (Basel)       Date:  2022-04-28       Impact factor: 4.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.